Hjem › Galdevejscancer › Minnesota
Galdevejscancer kliniske forsøg i Minnesota
5 studier for Galdevejscancer søger deltagere på steder i Minnesota.
Officiel studietekst (engelsk)
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- Masonic Cancer Center, University of Minnesota (Site 116), Minneapolis
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07265674A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Rochester
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07221253Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Rochester
RekruttererFase 3
Alder 18 til 99 · Alle køn · Opdateret 19. aug. 2026 · NCT06467357A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- M Health Fairview University of Minnesota Medical Center, Minneapolis
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- St. Luke's Hospital, Duluth
RekruttererFase 2
Alder 8 og opefter · Alle køn · Opdateret 27. jul. 2026 · NCT05503797Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.